BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

A Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Liver Impairment

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: BMS-986263

First Posted Date: 2020-01-13

Last Posted Date: 2021-11-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 40

Registration Number: NCT04225936

Locations: 🇺🇸
The Texas Liver Institute, San Antonio, Texas, United States

A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986165
Drug: Famotidine

First Posted Date: 2019-12-24

Last Posted Date: 2020-04-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 18

Registration Number: NCT04209699

Locations: 🇺🇸
PRA Health Sciences - Salt Lake, Salt Lake City, Utah, United States

A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer

Phase 3

Completed

Conditions: Bladder Tumor
Muscle-Invasive Bladder Cancer
Bladder Cancer

Interventions: Biological: Nivolumab
Procedure: Radical cystectomy (RC)
Biological: Bempegaldesleukin

First Posted Date: 2019-12-23

Last Posted Date: 2024-06-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 114

Registration Number: NCT04209114

Locations: 🇩🇪
Local Institution - 0117, Duesseldorf, Germany
🇨🇦
Local Institution - 0036, Sherbrooke, Quebec, Canada
🇨🇦
Local Institution - 0082, Oshawa, Ontario, Canada

and more 103 locations

A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: Ipilimumab

First Posted Date: 2019-12-12

Last Posted Date: 2019-12-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 10

Registration Number: NCT04196452

Locations: 🇺🇸
Local Institution, Princeton, New Jersey, United States

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

Phase 2

Completed

Conditions: Autoimmune Disorder
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Primary Sjögren's Syndrome

Interventions: Drug: branebrutinib
Drug: abatacept
Drug: branebrutinib placebo

First Posted Date: 2019-12-05

Last Posted Date: 2024-01-16

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 119

Registration Number: NCT04186871

Locations: 🇺🇸
Local Institution - 0083, Spokane, Washington, United States
🇺🇸
Local Institution - 0024, Encino, California, United States
🇫🇷
Local Institution - 0075, Brest, France

and more 71 locations

A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants

Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: BMS-986322
Drug: famotidine
Other: BMS-986322 Placebo

First Posted Date: 2019-11-25

Last Posted Date: 2022-05-31

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 171

Registration Number: NCT04175925

Locations: 🇺🇸
ICON (LPRA) - Lenexa, Lenexa, Kansas, United States

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea

Phase 3

Completed

Conditions: Psoriasis

Interventions: Other: Placebo
Drug: BMS-986165

First Posted Date: 2019-11-18

Last Posted Date: 2023-03-08

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 220

Registration Number: NCT04167462

Locations: 🇨🇳
Local Institution - 0031, Taipei, Taiwan
🇨🇳
Local Institution - 0012, Jingan, Shanghai, China
🇨🇳
Local Institution - 0014, Beijing, Beijing, China

and more 28 locations

A Study to Assess Overall Survival and Treatment Patterns for Advanced Liver Cancer Participants Who Received Nivolumab Therapy

Completed

Conditions: Hepatocellular Carcinoma

First Posted Date: 2019-11-13

Last Posted Date: 2019-11-13

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 1426

Registration Number: NCT04161911

Locations: 🇺🇸
Bristol Myers Squibb, CORDS Research, Princeton, New Jersey, United States

A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants

Phase 1

Completed

Conditions: Health Participants

Interventions: Drug: BMS-986209
Other: BMS-986209 Placebo
Drug: Itraconazole
Drug: Diltiazem

First Posted Date: 2019-11-07

Last Posted Date: 2022-01-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 114

Registration Number: NCT04154800

Locations: 🇺🇸
PPD Development, LP, Austin, Texas, United States

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Phase 1

Withdrawn

Conditions: Carcinoma, Non-small Cell Lung Cancer

Interventions: Biological: nivolumab
Biological: docetaxel
Biological: ipilimumab
Drug: lucitanib
Drug: cabozantinib
Biological: ramucirumab

First Posted Date: 2019-11-05

Last Posted Date: 2023-12-19

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT04151563

Locations: 🇷🇴
Local Institution, Timisoara, Romania

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy